In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Resverlogix Corp.

www.resverlogix.com

Latest From Resverlogix Corp.

Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path

Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.

Financing Business Strategies

Finance Watch: Investors Go Nuts For NASH As Madrigal Raises $300m, Galmed Skyrockets

Public Company Edition: Madrigal and Galmed shares more than doubled after reporting what were viewed as positive results in mid-stage NASH studies, with Madrigal going on to raise $300m on the back of the data. Not all is well for publicly traded firms, however, as Advaxis and Flex Pharma reveal layoffs.

Financing Business Strategies

Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year

Pharma and biotech companies raised $4.6bn in the first quarter, exceeding the 2017 quarterly average by $1.4bn. But while the money invested soared, the number of companies funded sank. In public financings, MorphoSys commences US IPO and Mylan sells $1.5bn in notes.

Deals Financing

Deals Shaping The Medical Industry, February 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2018.

Deals Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Neurology, Nervous System
  • Renal System
  • Alias(es)
  • Resverlogix Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Resverlogix Corp.
  • Senior Management
  • Donald J McCaffrey, Pres. & CEO
    Brad Cann, CFO
    Norman Wong, MD, CSO
    Kenneth Lebioda, SVP, Bus. & Corp. Dev.
  • Contact Info
  • Resverlogix Corp.
    Phone: (403) 254-9252
    300, 4820 Richard Rd. SW
    Calgary, T3E 6L1
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register